Pfizer’s high-profile, high-volatility Covid-19 franchise stabilized at the end of 2024, as the New York drugmaker pursues a revamp of its R&D operations and continues to cut costs.
Pfizer’s Covid pill Paxlovid and its vaccine ...
↧